Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.
Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.
Candel Therapeutics (Nasdaq: CADL) announced a $100 million royalty funding agreement with RTW to support a potential U.S. launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer, contingent on FDA approval and customary conditions.
Funds will be available upon approval; RTW will receive a tiered single-digit percentage of U.S. annual net sales, subject to a cap. Candel expects to submit a BLA in Q4 of this year and cites pivotal phase 3 data as the rationale for commercial potential.
Candel Therapeutics (Nasdaq: CADL) announced that Dr. Francesca Barone, Chief Scientific Officer, will present and take part in panels at the 7th Annual Glioblastoma Drug Development Summit in Boston, Feb 17–19, 2026. Presentations will cover the HSV-based platform and linoserpaturev (CAN-3110) program in recurrent high-grade glioma, focusing on biomarker-driven clinical development, imaging integration, and biomarker-based enrollment strategies to inform patient stratification and response assessment.
Candel Therapeutics (Nasdaq: CADL) announced inducement stock option grants made by its Compensation Committee on January 31, 2026. One new employee received options to purchase 6,600 shares at a per-share exercise price of $5.84 under the company’s 2025 Inducement Plan.
The options vest 25% after one year of service and the remaining 75% in 36 equal monthly installments, subject to continued employment. The Plan was adopted by the board on December 24, 2025.
Candel Therapeutics (Nasdaq: CADL) will host a virtual R&D Event on December 5, 2025 from 11:00 AM–1:45 PM ET. The program includes executive presentations, scientific panels, and collaborator talks offering an extensive overview of Candel’s viral immunotherapy approach and oncology pipeline, including CAN-2409 and CAN-3110 programs.
Featured speakers include CEO Paul Peter Tak, MD, PhD, Nobel Laureate James P. Allison, Carl H. June, MD, and clinical and regulatory leads covering BLA and pre-commercialization roadmaps. Live webcast and replay will be available on the company Investors page with registration required.
Candel Therapeutics (NASDAQ: CADL) reported Q3 2025 results and corporate updates on November 13, 2025. Key clinical progress includes subgroup phase 3 data for CAN-2409 in localized prostate cancer showing improved prostate cancer-specific DFS (HR 0.62; p=0.0046), plans to submit a BLA in Q4 2026, and intent to start a pivotal phase 3 in NSCLC in Q2 2026. Updated survival data for CAN-3110 in recurrent high-grade glioma showed median OS ~11.8–12.0 months in arms A/B. Financially, the company has $87.0M cash (9/30/25) and closed a $130M term loan with $50M drawn at signing to fund operations into Q1 2027.
Candel Therapeutics (Nasdaq: CADL) will present three data sets at SITC 2025 highlighting clinical and preclinical advances in viral immunotherapies and AI‑driven design.
Key points: a Phase 3 study of CAN‑2409 in newly diagnosed, localized prostate cancer met its primary endpoint and the company plans a BLA submission in Q4 2026; Phase 2a MOFA biomarker analysis in NSCLC showed stronger immune activation and prolonged overall survival in non‑squamous vs squamous histology; an AI‑designed candidate (Alpha‑201 IL‑12/15) produced 60.0%±12.6 tumor growth suppression in an EMT6 breast cancer mouse model.
Candel Therapeutics (Nasdaq: CADL) announced that Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO, will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 from 8:00–8:25 AM GMT (4:00–4:25 AM ET). The presentation will be webcast and available under Events and Presentations in the Investors section at www.candeltx.com. A replay will be archived for up to 90 days after the session.
Candel Therapeutics (Nasdaq: CADL) announced the appointment of Bali Pulendran, Ph.D. to its Research Advisory Board on October 16, 2025. Dr. Pulendran is a systems immunology and vaccinology expert, Violetta L. Horton Professor at Stanford, Director of the Institute for Immunity, Transplantation and Infection, and a Thomson Reuters Highly Cited Researcher.
He will advise as Candel advances lead viral immunotherapy candidates CAN-2409 across multiple solid tumors and CAN-3110 for recurrent high-grade glioma, bringing expertise in dendritic cell biology and human immune-response systems.
Trinity Capital (Nasdaq: TRIN) committed $130 million in growth capital to Candel Therapeutics (Nasdaq: CADL) on October 14, 2025 to support development of viral immunotherapies.
The funding is earmarked to support clinical development of CAN-2409 and pre-commercial and launch readiness activities for CAN-2409 in prostate cancer pending regulatory approval. Candel's pipeline includes CAN-2409 and CAN-3110 targeting solid tumors (prostate, pancreatic, lung, brain).
Candel has received multiple FDA designations: RMAT for localized prostate cancer, Fast Track for localized prostate and non-small cell lung cancer, and dual Fast Track and Orphan Drug designations for pancreatic and brain cancer programs.
Candel Therapeutics (Nasdaq: CADL) entered a five-year $130 million term loan facility with Trinity Capital on Oct 14, 2025, with $50 million drawn at closing and access to up to an additional $80 million across three tranches.
The facility carries an initial interest option of 10.25% per annum, a 36-month interest-only period (extendable 12 months upon a commercial milestone), and contains customary covenants and events of default. Candel reported $87.2 million cash as of Sept 30, 2025. Proceeds will refinance an existing loan and fund working capital, initiation of a pivotal phase 3 CAN-2409 NSCLC trial planned for Q2 2026, and prepare for a potential BLA submission in prostate cancer in Q4 2026.